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Abstract 
AIM: To evaluate the effect of a novel alginate-based 
compound, Faringel, in modifying reflux characteristics 
and controlling symptoms.
METHODS: In this prospective, open-label study, 40 
patients reporting heartburn and regurgitation with 
proven reflux disease (i.e., positive impedance-pH test/
evidence of erosive esophagitis at upper endoscopy) 
underwent 2 h impedance-pH testing after eating a re-
fluxogenic meal. They were studied for 1 h under basal 
conditions and 1 h after taking 10 mL Faringel. In both 
sessions, measurements were obtained in right lateral 
and supine decubitus positions. Patients also com-
pleted a validated questionnaire consisting of a 2-item 
5-point (0-4) Likert scale and a 10-cm visual analogue 
scale (VAS) in order to evaluate the efficacy of Faringel 
in symptom relief. Tolerability of the treatment was as-
sessed using a 6-point Likert scale ranging from very 
good (1) to very poor (6).
RESULTS: Faringel decreased significantly (P < 0.001), 
in both the right lateral and supine decubitus positions, 
esophageal acid exposure time [median 10 (25th-
75th percentil 6-16) vs  5.8 (4-10) and 16 (11-19) vs  
7.5 (5-11), respectively] and acid refluxes [5 (3-8) vs  
1 (1-1) and 6 (4-8) vs  2 (1-2), respectively], but in-
creased significantly (P  < 0.01) the number of nonacid 
reflux events compared with baseline [2 (1-3) vs  3 (2-5) 
and 3 (2-4) vs  6 (3-8), respectively]. Percentage of 
proximal migration decreased in both decubitus posi-
tions (60% vs  32% and 64% vs  35%, respectively; P  
< 0.001). Faringel was significantly effective in con-
trolling heartburn, based on both the Likert scale [3.1 
(range 1-4) vs  0.9 (0-2); P  < 0.001] and VAS score 
[7.1 (3-9.8) vs  2 (0.1-4.8); P  < 0.001], but it had less 
success against regurgitation, based on both the Likert 
scale [2.6 (1-4) vs  2.2 (1-4); P  = not significant (NS)] 
and VAS score [5.6 (2-9.6) vs  3.9 (1-8.8); P  = NS]. 
Overall, the tolerability of Faringel was very good 5 
(2-6), with only two patients reporting modest adverse 
events (i.e., nausea and bloating).
CONCLUSION: Our findings demonstrate that Faringel 
is well-tolerated and effective in reducing heartburn by 
modifying esophageal acid exposure time, number of 
acid refluxes and their proximal migration. 
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INTRODUCTION
Gastroesophageal reflux disease (GERD) is a common 
problem affecting about 20% of  the population in west-
ern countries[1]. Nonerosive reflux disease (NERD) and 
erosive reflux disease (ERD) represent the most com-
mon phenotypic presentations of  GERD, accounting 
for 90%-95% of  the overall GERD patients[2]. Previous 
studies have documented that patients with ERD and 
NERD present the same clinical picture in terms of  fre-
quency and severity of  reflux symptoms[2,3]. 
To date, the use of  proton pump inhibitors (PPIs) 
has been considered the best therapeutic option for 
GERD patients, given their high efficacy in determin-
ing symptom relief  and in inducing esophageal muco-
sal healing[4,5]. On the other hand, there is increasing 
evidence that not all patients respond satisfactorily to 
this kind of  treatment and that about 30%-35% of  the 
patients require additional intervention to control symp-
toms[6-8]. Thus, traditional antacids are frequently used 
as add-on therapy in order to neutralize gastric acidity 
and to help control of  heartburn[7,9,10]. However, there 
are limited data regarding the mechanisms by which they 
are able to modify the determinants of  reflux symptom 
perception[11]. Moreover, despite their utility, the majority 
of  current antacid formulations are not well tolerated by 
patients and this limits their widespread use and efficacy.
Recently, a novel compound, Faringel (CADIGroup, 
Rome, Italy), containing sodium bicarbonate and algi-
nate with the addition of  herbal components (i.e., honey, 
chamomille or Matricaria recutita L., Calendula officinalis, Aloe 
vera, Propolis gel) has been introduced to the market. The 
first two elements are well known to have an antireflux ef-
fect due to their ability to neutralize gastric acidity and to 
create an alginate-based raft that remains in the upper part 
of  the stomach as a physical barrier capable of  prevent-
ing reflux episodes[12-15], while the latter components have 
been recently associated with mild anti-inflammatory and 
analgesic effects, and it has been suggested that they may 
favor the healing of  human mucosa[16-22].
In recent years, multichannel intraluminal impedance 
combined with pH-metry (MII-pH) has been applied to 
assess the effectiveness of  drugs or endoscopic devices 
proposed for the therapy of  GERD, particularly if  we 
want to know whether they can affect both acid and 
nonacid reflux or are able to reduce the proximal migra-
tion of  the refluxate[23-26].
The aim of  the present study was to evaluate the anti-
reflux properties of  an alginate antacid formulation (Far-
ingel) on both acid and nonacid reflux episodes, and the 
height of  the proximal extent of  reflux events by means 
of  MII-pH monitoring in patients with documented mild 
to moderate GERD. As a secondary aim, we assessed the 
therapeutic efficacy of  this novel compound as well as its 
tolerability using validated questionnaires.
MATERIALS AND METHODS
Subjects
This was a prospective, open-label study, enrolling con-
secutive patients with typical reflux symptoms (i.e., heart-
burn and regurgitation) lasting for > 6 mo and occurring 
at least three times weekly, presenting to the University 
Hospital of  Genova and to the University Hospital of  
Pisa, Italy. They were referred to our units because they 
were undergoing upper endoscopy, preoperative surgical 
evaluation, or being investigated for PPI refractoriness. 
Exclusion criteria were: history of  thoracic, esophageal 
or gastric surgery; primary or secondary severe esopha-
geal motility disorders (e.g., achalasia, scleroderma, dia-
betes mellitus, autonomic or peripheral neuropathy, my-
opathy); or history of  alcohol or drug abuse. In women 
of  childbearing age, pregnancy was excluded by urine 
analysis. 
For comparison, normal values were obtained from a 
group of  48 healthy volunteers [HVs; 22 male; mean age 
44 years, range 22-77 years; mean body mass index (BMI) 
23 kg/m2, range 16-34 kg/m2] without any type of  di-
gestive and systemic symptoms, and previously studied 
in our laboratory[27].
The study protocol was approved by the local Ethics 
Committee and performed according to the Declaration 
of  Helsinki. All patients provided written informed con-
sent to take part.
Study protocol
All subjects who agreed to undergo both upper gastro-
intestinal (GI) endoscopy and 24-h esophageal imped-
ance pH, underwent physical and clinical examination 
and a detailed medical history was recorded. The medi-
cal history included information on their symptomatic 
response to previous PPI therapy taken for at least 8 wk 
at double dose. Patients reporting < 50% heartburn im-
provement were considered nonresponders to PPIs (i.e., 
heartburn more than twice weekly for at least 2 mo). 
Patients taking antisecretory or prokinetic drugs were 
asked to stop any medication at least 30 and 15 d before 
endoscopy, respectively. Antacids or alginate prepara-
tions were suggested in case of  frequent symptoms. The 
frequency and intensity of  symptoms and impact on 
quality of  life were registered using a structured and vali-
dated questionnaire for the diagnosis of  GERD[28]. 
Thereafter, within 1-5 d (median 3 d) from the up-
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per GI endoscopy, every patient underwent esophageal 
impedance-pH testing off-therapy using an ambulatory 
multichannel intraluminal impedance and pH (MII-pH) 
monitoring system (Sleuth, Sandhill Scientific, Highland 
Ranch, CO, United States), according to our methodolo-
gy[27]. During the test day, meal time and composition were 
standardized[29]. Stationary esophageal manometry was 
performed before MII-pH in order to locate with accu-
racy the lower esophageal sphincter (LES). Other features 
regarding the variables of  reflux measurement by MII-pH 
and data analysis have been previously reported[30,31]. 
After the 24-h monitoring period, patients returned 
to our hospital service. Based on the results of  endos-
copy and impedance-pH testing, patients were classified 
as NERD, in case of  absence of  esophageal mucosal 
breaks in combination with an abnormal esophageal acid 
exposure time and/or a positive symptom association 
probability (> 95%) to acid and/or nonacid reflux dur-
ing impedance-pH monitoring[3,27], and as ERD, in case 
of  presence of  esophageal mucosal injury according 
to international criteria[32]. Furthermore, patients with 
hypersensitive esophagus (i.e., normal upper endoscopy, 
normal MII-pH testing, and positivity for symptom 
association analysis) were ruled out from the whole 
group of  NERD in order to include patients with well-
documented GERD. Then, they were asked to ingest a 
refluxogenic meal consisting of  a continental breakfast 
[one cappuccino, two brioches containing chocolate 
cream (450 kcal, 60%) fat and orange juice], at least 4 h 
after the breakfast, and completed two questionnaires in-
cluding questions on the presence and intensity of  heart-
burn and regurgitation after the meal, as well as a 10-cm 
visual analogue scale (VAS) scale for each one of  the two 
symptoms (see below). Patients underwent an additional 
2-h period of  recording; 1 h under basal conditions 
and another 1 h after a single dose (10 mL) of  Faringel. 
Studies were performed while patients laid in the right 
lateral decubitus position for 30 min and in the supine 
decubitus position for another 30 min; both under basal 
conditions and after Faringel treatment. In particular, the 
right lateral decubitus position was chosen because it has 
been shown to be associated with an increased esopha-
geal acid exposure[33]. Afterward, data recording was con-
cluded. Between the two sections and at the end of  the 
test, patients filled out both symptomatic questionnaires.
Symptom assessment
The primary efficacy parameter was the change in the 
sum score of  the validated Likert scale[34,35] filled in by 
the investigator. Intensity of  heartburn (defined as a 
retrosternal burning sensation occurring in waves and 
tending to rise upward toward the neck) and regurgita-
tion (return of  partially digested food from the stomach 
to the mouth) during the test was recorded by interview-
ing the patient, using a 5-point Likert rating scale as fol-
lows: 0 = none (absence of  symptoms); 1 = mild (minimal 
awareness of  symptoms, which is easily tolerated); 2 = 
moderate (awareness of  symptoms, which is bothersome 
but tolerable); 3 = severe (symptoms hard to tolerate); 
4 = very severe (symptom impossible to tolerate). The 
score was used for the outcome measurement as a sum 
score, with its highest value of  8 points representing the 
most severe symptom intensity.
Patients were also asked to rate their satisfaction with 
symptom control on a global VAS of  0 (no relief  at all) 
to 100 (complete symptom relief). The VAS score has 
been used as a self-assessment tool for symptom mea-
sure, which has been adopted in many other trials for 
evaluation of  visceral symptoms[36,37].
The secondary target variable comprised the overall 
tolerability of  the treatment, assessed by investigator and 
patient using a 6-point Likert scale ranging from very 
poor (1) to very good (6). Together with the exploratory 
target variables, the number of  responders and patients 
free of  symptoms were also studied. Responders were 
defined as patients for whom a 40% improvement in 
the Likert scale was achieved, whereas patients free of  
symptoms were defined as subjects showing an overall 
sum score of  0 or 1 point when treatment stopped. 
Statistical analysis
Differences in proportions were compared using the χ 2 
or Fisher’s exact test, depending on the sample size. Un-
less otherwise specified, data were presented as median 
and percentile values (25th, 75th, 95th percentile). In 
case of  non-normally distributed data, differences be-
tween patients were compared using the Kruskal-Wallis 
and/or Mann-Whitney tests. Differences were consid-
ered statistically significant at P < 0.05. 
RESULTS
Patients
Forty patients with heartburn (20 female/20 male, mean 
age 48 years, range 18-76 years) reporting at least one 
symptom during the testing day were included in the 
study. Detailed demographic and clinical features of  
GERD patients and HVs are shown in Table 1. There 
was no difference among them and HVs in terms of  sex 
and age. The prevalence of  hiatal hernia as well as mean 
BMI was significantly higher in patients with GERD 
compared to the HVs (P < 0.01). All subjects tolerated 
well the examination and the test meal. No important 
technical failure occurred.
24-h impedance-pH data 
Detailed impedance-pH characteristics of  our patients 
and HVs are reported in Table 2. Patients with GERD 
had significantly greater distal esophageal acid exposure 
time compared to HVs (5.5 vs 0.7, P < 0.0001). The 
median total number of  reflux episodes was 65 and the 
median number of  acid reflux events was 53, and both 
were significantly higher in GERD patients compared to 
HVs (32 and 17, respectively; P < 0.0001). Patients with 
GERD and HVs had a similar number of  nonacid reflux 
episodes (20 vs 18, P < 0.0615). The percentage of  total 
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reflux episodes reaching the proximal measuring site (15 
cm above the LES) was higher in GERD patients than 
in HVs (46% vs 33%, P < 0.0001).
2-h impedance-pH data before and after treatment 
As shown in Figures 1 and 2A, Faringel decreased sig-
nificantly (P < 0.001), in both the right lateral and supine 
decubitus positions, esophageal acid exposure time [10 
(6-16; 23) vs 5.8 (4-10; 16) and 16 (11-19; 32) vs 7.5 (5-11; 
15), respectively], acid reflux events [5 (3-8; 11) vs 1 (1-1; 
2) and 6 (4-8; 11) vs 2 (1-2; 5), respectively], and proximal 
reflux episodes [4 (3-6; 11) vs 1 (1-2; 3) and 5 (4-7; 11) vs 
3 (2-3; 4), respectively]. Also, the percentage of  proximal 
migration of  reflux events decreased significantly in both 
the right lateral and supine decubitus positions (60% vs 
32% and 64% vs 35%) compared with baseline. In con-
trast, Faringel increased significantly (P < 0.01) the num-
ber of  nonacid reflux events compared with baseline [2 
(1-3; 5) vs 3 (2-5; 7) and 3 (2-4; 7) vs 6 (3-8; 13); Figure 
2B]. The number of  total reflux episodes slightly signifi-
cantly decreased in the right lateral decubitus position, 
before and after Faringel treatment, while no difference 
was found in the supine decubitus position [7 (5-10; 15) 
vs 4 (3-5; 10) and 8.5 (7-11; 16) vs 7 (5-10; 17), P = 0.0001 
and P = 0.1321, respectively].
Symptom relief and drug tolerability 
Patients reported a greater mean (range) number of  
symptoms before than after treatment and this included 
both heartburn [2.5 (1-9) vs 1 (0-2)] and regurgitation [2 
(1-5) vs 1 (0-2)]. Faringel was found to be significantly 
effective in controlling heartburn, based on the both 
Likert scale [3.1 (range 1-4) vs 0.9 (0-2); P < 0.001] and 
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  Demographic and clinical 
  parameters GERD patients HVs P value
  Patients   40  48
  Female/male   20/20  27/21 NS
  Mean age, yr (range)   48 (18-76)  44 (22-77) NS 
  Mean BMI, kg/m2 (range)   26 (20-32)  23 (16-34) < 0.05
  NERD/ERD   25 (63)/15 (38)  NA
  Patients with hiatal hernia   22 (55)    4 (10) < 0.01
  Patients responding to PPI therapy   34 (85)  NA
Table 1  Demographic and clinical characteristics of gastro-
esophageal reflux disease patients and healthy volunteers  n (%)
NERD: Nonerosive reflux disease; ERD: Erosive reflux disease; GERD: 
Gastroesophageal reflux disease; PPI: Proton pump inhibitor; BMI: Body 
mass index; HV: Healthy volunteer.
  Impedance-pH features GERD patients HVs P  value
  % pH < 4 upright     6.9 (5.5-12; 28) 1 (0.2-1.9; 5) < 0.0001
  % pH < 4 recumbent     3.5 (1.2-7; 18) 0 (0-0.1; 2.1) < 0.0001
  % pH < 4 total     5.5 (4.3-9; 22) 0.7 (0.2-1.4; 4.2) < 0.0001
  GER total   65 (54-108; 177) 32 (18-43; 54) < 0.0001
  GER acid   53 (34-72; 95) 17 (8-31; 45) < 0.0001
  GER nonacid   20 (15-37; 116) 18 (14-26; 45)     0.0615
  Prox. extension   31 (20-48; 86) 9 (4-17; 30) < 0.0001
Table 2  Impedance-pH features in gastro-esophageal reflux 
disease patients and healthy volunteers
GER: Gastroesophageal reflux; GERD: Gastroesophageal reflux disease; 
HV: Healthy volunteer.
Figure 1  Median esophageal acid exposure under basal conditions and 
after Faringel intake in the two decubitus positions.
Figure 2  Number of acid reflux (A) and non-acid reflux (B) episodes under 
basal conditions and after Faringel intake in the two decubitus positions.
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VAS score [7.1 (3-9.8) vs 2 (0.1-4.8); P < 0.001), while it 
had less success against the symptom regurgitation based 
on both the Likert scale [2.6 (1-4) vs 2.2 (1-4); P = not 
significant (NS)] and VAS score [5.6 (2-9.6) vs 3.9 (1-8.8); 
P = NS]. Overall, the tolerability of  Faringel was very 
good [5 (2-6)], with only two patients reporting modest 
adverse events (i.e., nausea and bloating).
DISCUSSION
Alginates are neutral polysaccharide polymers isolated 
from brown seaweed (Phacophycae) and are classified as 
dietary fiber. They are constituted by a proportion of  
D-mannuroic and L-glucuronic acids. In the presence 
of  gastric acid, alginates precipitate and form a gel. One 
of  the most interesting characteristics is due to the pres-
ence of  sodium or potassium bicarbonate that, in the 
presence of  gastric acid is converted to a dioxide which, 
when entrapped in the gel, converts it into a foam that 
floats on the surface of  the gastric contents[12]. Thus, 
thanks to their unique mechanism, alginate-based raft-
forming formulations have been marketed worldwide 
for > 40 years under various brand names for the symp-
tomatic treatment of  GERD, and many studies have 
reported their efficacy[12,38,39]. However, the majority of  
these studies have assessed only the control of  symp-
toms without objective evaluation of  the effect of  these 
drugs on abnormal reflux by means of  pH-monitoring, 
and and even less using impedance-pH testing that is 
available in the clinical setting since few years.
Therefore, in our prospective study we evaluated 
the effect of  a new alginate raft-forming formulation, 
Faringel, in a group of  40 patients with GERD who un-
derwent 24 h MII-pH testing after a reflux-provocative 
meal. Our results showed that this alginate-based formu-
lation is able to reduce the number of  acid refluxes and 
the esophageal exposure time below pH 4.0. Moreover, 
it is able to decrease significantly, in both the right lateral 
and supine decubitus position, the number of  acid reflux 
events and their proximal migration. Finally, all patients 
also reported a lower number of  symptoms after treat-
ment, including both heartburn and regurgitation, al-
though the effect on the latter was less evident.
The patients evaluated in the present study were 
truly representative of  the GERD population. Indeed, 
they had typical reflux symptoms (i.e., heartburn and 
regurgitation), abnormal acid exposure time, and/or 
evidence of  mucosal breaks at upper GI endoscopy. 
We opted to include patients with these characteristics 
in order to be sure of  excluding those with functional 
heartburn. Moreover, we preferred not to enroll patients 
with normal acid exposure and positive symptom asso-
ciation (i.e., hypersensitive esophagus) for reducing pos-
sible confounding factors such as visceral hyperalgesia, 
overlap with functional disease, autonomic dysfunction 
and concomitant psychiatric illness that have been more 
associated with the above condition[40-43]. Finally, a recent 
report has suggested caution about overinterpretation 
of  symptom indexes in reflux monitoring, thus support-
ing our decision to exclude patients with hypersensitive 
esophagus in order to avoid confusion[44].
Previously, Chatfield has reported a comparison of  
alginate preparation with placebo for the symptomatic 
relief  of  reflux esophagitis[39]. In this multicenter ran-
domized double-blind study, alginate was superior to pla-
cebo in reducing symptom severity and increasing symp-
tom-free days. Interestingly, the placebo group recorded 
a larger number of  dropouts due to side effects. This 
means that alginate is safe and provides better relief  of  
symptoms. An older study that simultaneously used pH-
telemetry and X-rays demonstrated that pH within the 
raft is approximately neutral, while the pH of  the gastric 
contents beneath the raft remains acidic (pH 1-2)[45]. 
These data are important because they explain why the 
alginate formulation is effective in controlling heartburn 
in the supine decubitus position, as observed in this 
study, and probably also during the night-time. More 
recently, using impedance-pH monitoring, we showed a 
reduction of  acid reflux episodes and proximal migra-
tion of  the refluxate and thereby a relevant decrease of  
GERD-related symptoms compared with baseline after 
sodium alginate administration[7]. However, the results 
of  the latter study were less marked than those of  the 
current investigation, probably because patients were en-
rolled only on the basis of  symptoms without objective 
documentation of  GERD, either by endoscopy or pH 
monitoring. Moreover, in the previous study, tolerability 
was not evaluated.
The good control of  acid reflux confirms the results 
obtained in previous studies performed with pH-me-
try[7,14,46,47] or scintigraphic methods[48,49], and represents 
the main mechanism of  the quick and effective relief  of  
heartburn in reflux patients. In a recent study, the posi-
tive effect of  sodium alginate in reducing acid refluxes 
has been confirmed using simultaneously stepwise pH 
pull-throughs, high-resolution manometry and fluoros-
copy[15]. In fact, Kwiatek et al[15] have shown that alginate 
can also eliminate or displace the “acid-pocket”, which 
is a phenomenon seen in the proximity of  the esopha-
gogastric junction and is the likely origin of  postprandial 
acid reflux in GERD patients. 
Another interesting characteristic of  sodium alginate 
has been emphasized by Manabe et al[50] in NERD pa-
tients, who are known to have a lower response rate to 
PPIs than patients with ERD when gauged by relief  of  
heartburn. In this study, patients who received omepra-
zole combined with sodium alginate recorded longer 
symptom relief  compared with those receiving omepra-
zole alone. They concluded that sodium alginate is useful 
in combination with PPI therapy and has to be consid-
ered for treating NERD patients who do not respond 
completely to PPIs. Also, in our investigation, we evalu-
ated NERD patients and found similar results on symp-
tom relief  in this particular group of  GERD patients, 
although we did not study Faringel as an add-on therapy.
It is likely that the positive effect of  sodium algi-
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nate in controlling GERD-related symptoms is due to 
a whole equilibrium between raft-forming alginate and 
antacid substances. Faringel is constituted from sodium 
alginate and sodium carbonate. A previously published 
study has shown that, if  two different antacid substances 
are present (e.g., Algicon Liquid), an effective reflux sup-
pressing raft cannot form because a large amount of  
antacid prevents the raft formation by neutralizing the 
gastric acid required to react with alginate. Faringel and 
Gaviscon formulation consist of  sodium alginate and so-
dium carbonate, and they have a lower acid-neutralizing 
capacity and a complete raft-forming gel reaction[13,47,49]. 
These studies have shown that a large amount of  antac-
ids is not required for strong raft formation and effective 
reflux suppression. 
On the contrary, various findings suggest that algi-
nate is less effective in reducing nonacid than acid reflux. 
In our study alginate increased significantly the num-
ber of  nonacid reflux events compared with baseline. 
The number of  total reflux episodes decreased slightly 
but significantly in the right lateral decubitus position, 
whereas no difference was found in the supine decubitus 
position. Similarly, Zentilin et al[7] have shown no action 
of  alginate on nonacid reflux events. Surprisingly, in our 
study, the number of  nonacid reflux episodes almost 
doubled after drug intake in 50% of  patients. Probably 
the antacid effect of  sodium alginate reduces acid reflux, 
but seems to increase nonacidic reflux.
Finally, our study shows that the percentage of  proxi-
mal migration of  reflux events decreased significantly 
both in the right lateral and supine decubitus positions 
compared with baseline, thus stopping one of  the main 
determinants by which reflux causes symptoms[51-53]. 
These results confirm our previous findings with a differ-
ent sodium alginate formulation, although the study was 
performed in a smaller sample of  patients and without 
a clear documentation of  GERD[7]. These investigations 
performed with impedance-pH monitoring technique 
permitted us to assess the ability of  sodium alginate to re-
duce the proximal extension of  refluxed material. The raft 
obtained with alginate represents a cork in the zone of  the 
LES that prevents any gastric material migration into the 
esophagus independently of  the patient decubitus. This 
beneficial effect could help in controlling not only typical, 
but especially extraesophageal symptoms. In particular, 
the Faringel formulation adds to alginate able to control 
GERD related typical symptoms a large number of  veg-
etal extracts, which have the potential to promote healing 
of  pharyngoesophageal mucosal lesions. The anti-flogistic 
properties of  Faringel are due to herbs such as Propolis, 
A. vera, and Calendula. Eamlamnam et al[54] have observed 
that A. vera treatment induces a complete reduction in 
leukocyte adherence and tumor necrosis factor-α levels 
combined with elevated interleukin-10 levels, which are 
able to promote healing of  gastric ulcers in male Sprague-
Dawley rats. Propolis and A. vera have also demonstrated 
pain-killing effects[55]. Moreover, experimental studies have 
shown that C. officinalis has anti-inflammatory and anti-
bacterial activities as well as angiogenic and fibroblastic 
properties acting in a positive way on the inflammatory 
and proliferative phase of  the healing process[20]. Thus, 
we can speculate that all these data on the anti-inflam-
matory properties of  the herbal components of  Faringel 
may be relevant for extraesophageal reflux-related symp-
toms in which a flogistic component seems to be more 
evident[56].
In conclusion, our findings demonstrated that Farin-
gel formulation is well tolerated and highly effective in 
controlling, or at least reducing, heartburn in GERD pa-
tients by modifying the number of  acid reflux episodes 
and lowering the proximal migration of  reflux events. It 
was less effective in controlling nonacid reflux and re-
gurgitation. Its action in reducing the proximal extension 
of  reflux events and the combined presence of  natural 
substances (Calendula, Aloe, honey) that favor mucosal 
healing could be useful to improve GERD-related extra-
esophageal symptoms.
COMMENTS
Background
The use of proton pump inhibitors (PPIs) has been considered the best thera-
peutic option for gastroesophageal reflux disease (GERD), given their high effi-
cacy in inducing symptom relief and esophageal mucosal healing. On the other 
hand, there is increasing evidence that not all patients (30%-35%) respond 
satisfactorily to this treatment. Thus, traditional antacids as alginate-based raft-
forming formulations are used worldwide as add-on therapy to neutralize gastric 
acidity and help control heartburn. In recent years, multichannel intraluminal 
impedance combined with pH-metry (MII-pH) has been applied to assess 
the effectiveness of drugs or endoscopic devices proposed for the therapy of 
GERD, particularly if people want to know whether they can affect both acid 
and nonacid reflux or reduce the proximal migration of the refluxate. 
Research frontiers
There are few data available regarding the mechanisms by which antacids as 
alginate-based raft-forming formulations are able to modify the determinants of 
reflux symptom perception, therefore, this study tried to evaluate the antireflux 
properties of an alginate antacid formulation (Faringel) on both acid and nonac-
id reflux episodes, and the height of proximal extent of reflux events by means 
of MII-pH monitoring in patients with documented mild to moderate GERD. As 
a secondary aim, authors assessed the therapeutic efficacy of this novel com-
pound as well as its tolerability using validated questionnaires. 
Innovations and breakthroughs
In this prospective, open-label study, 40 patients reporting heartburn and regur-
gitation with proven reflux disease (i.e., positive impedance-pH test/evidence 
of erosive esophagitis at upper endoscopy) underwent 2-h impedance-pH test 
after eating a refluxogenic meal. They were studied for 1 h under basal condi-
tions and 1 h after taking 10 mL Faringel. Patients also completed validated 
questionnaires in order to evaluate the efficacy of Faringel for symptom relief. 
Tolerability of the treatment was also assessed.
Applications
The results suggest that Faringel is able to reduce the esophageal acid ex-
posure time, the number of acid reflux events and their proximal migration, 
thus stopping two of the main determinants by which reflux causes symptoms 
(i.e., abnormal esophageal acid exposure time and proximal extension of the 
refluxate). Moreover, Faringel was very well-tolerated and effective in reducing 
heartburn and regurgitation, although the efficacy on the latter symptom was 
less evident.
Terminology
GERD is a condition that develops when the reflux of stomach contents causes 
troublesome symptoms and/or complications; Faringel is an antacid formula-
tion, containing sodium bicarbonate and alginate with the addition of herbal 
components (i.e., honey, Chamomille or Matricaria recutita L., Calendula of-
ficinalis, Aloe vera, Propolis gel) that have been recently associated with mild 
anti-inflammatory and analgesic effects; MII-pH is a novel technique for pH-
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independent detection of GER.
Peer review
The study is interesting, well conducted, with a clear statistical analysis and a 
comprehensive discussion. 
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